Vesugen (KED) | Dosage Peptide
🧬 Tripeptide Bioregulator

Vesugen (KED)

Synthetic tripeptide studied for vascular endothelium support and neuroplasticity through epigenetic gene regulation via DNA/histone interactions.

Sequence Lys–Glu–Asp
MW ~390.39 Da
PubChem 87571363

⚡ Executive Summary

Vesugen (KED) is a research-only tripeptide investigated as a vascular and neuroprotective "bioregulator." Early work suggests KED can normalize endothelin-1, restore connexins, and increase SIRT1 in endothelial cells, and support dendritic structure/neurogenesis markers in neuronal models. Human evidence remains limited.

Jump to section

01 Overview 02 Properties 03 Mechanism 04 Research 05 Handling 06 Comparison
📋

Overview

🧬 What is Vesugen?

Vesugen is a short, three-amino-acid peptide (Lys–Glu–Asp) studied as a tissue-specific "bioregulator" for vascular endothelium and brain.

It belongs to a family of ultrashort peptides investigated for epigenetic control of gene expression—by binding to DNA promoter motifs and/or histone proteins.

🎯 Primary Research Focus

  • 🫀
    Vascular endothelium — vasoprotective gene shifts
  • 🧠
    Neuroplasticity — dendritic support in AD models
  • 🧬
    Epigenetic regulation — DNA/histone interactions
⚠️

Compliance note: This article is educational for researchers, not medical advice. No human use is endorsed or implied.

🔬

Entity Properties

Aliases Vesugen, Vezugen, KED, Lys–Glu–Asp
Sequence H-Lys-Glu-Asp-OH (K-E-D)
Molecular Weight ~390.39 Da
Formula C₁₅H₂₆N₄O₈
PubChem CID 87571363
Diluent(s) SWFI; BWFI (0.9% benzyl alcohol)
Concentration 1–2 mg/mL in aqueous media
Storage (lyophilized) ≤ −20°C, desiccated, light-protected
Storage (solution) Cold, short-term; avoid freeze-thaw
⚙️

Mechanism of Action

🧠 How does KED work?

KED's proposed mechanism is epigenetic modulation of gene transcription via direct interactions with DNA and nucleosomal histones—a behavior repeatedly documented for ultrashort peptides in vitro, in silico, and by biophysical methods.

🔗 DNA Binding

KED → GCCG sequence in promoter regions (sequence-selective DNA interactions)

📊 EDN1

Normalizes endothelin-1 levels in endothelial models for vascular homeostasis

🔄 Connexins

Re-expression of Cx37/Cx40/Cx43 for cell-to-cell communication

🎯 Target Pathways

🫀
Vascular

EDN1, GJA1/Cx43, SIRT1, MKI67

→ Vasoprotective phenotypes
🧠
Neuro

NES, GAP43, p16/p21, SUMO1

→ Dendritic support
🔄
Cell Cycle

MKI67 promoter, Ki-67

→ Controlled proliferation
🧬
Epigenetic

DNA binding, histone tails

→ Transcription cues
📊

Research Outcomes

🫀 Vascular Research

In endothelial and vascular injury contexts, KED showed gene-level changes consistent with improved microvascular homeostasis:

  • ✓
    EDN1 normalization in atherosclerosis models
  • ✓
    Connexin re-expression (Cx37/Cx40/Cx43)
  • ✓
    SIRT1 increases — anti-senescence

🧠 Neuroplasticity Research

In Alzheimer's disease (AD) models, KED showed promising neuronal outcomes:

  • ✓
    Preserved dendritic spines in 5xFAD mice
  • ✓
    Improved dendritic arborization
  • ✓
    Modulated genes: NES, GAP43, p16/p21

👥 Clinical Evidence

Evidence in humans is limited and heterogeneous. A small Russian geriatric study suggested oral Pinealon + Vesugen improved cognitive/functional measures.

⚠️

These findings require larger, controlled replication. No regulatory approvals exist; robust randomized trials are lacking.

🧪

Handling & Storage

📘

Education-only. Follow your institution's SOPs, validated methods, and biosafety rules.

1

Plan & Document

Define assay, endpoints (EDN1 mRNA, Cx43, dendritic length).

2

Confirm Identity

Log K-E-D, MW ~390.39 Da, PubChem CID in ELN/LIMS.

3

Choose Diluent

SWFI for single-use; BWFI for multi-withdrawal vials.

4

Reconstitute

Warm vial, 1–2 mg/mL, mix gently, avoid foaming.

5

Aliquot & Label

Single-use aliquots. Label: ID/lot/conc/expiry.

6

Store Properly

Lyophilized ≤ −20°C; solution cold, short-term.

⚖️

Comparison

KED (Vesugen) is vascular-centric with neuroplasticity crossover, whereas Pinealon (EDR) is neuro-centric and Epitalon (AEDG) is genome/aging-centric. All three are short peptides investigated for epigenetic regulation.

Vesugen (KED)

Lys–Glu–Asp (tripeptide)
🫀 Vascular + 🧠 Neuro

EDN1 normalization, connexin restoration, SIRT1↑. Dendritic support.

Pinealon (EDR)

Glu–Asp–Arg (tripeptide)
🧠 Neuroprotection

Dendritic spines, dendritogenesis, oxidative stress responses.

Epitalon (AEDG)

Ala–Glu–Asp–Gly (tetrapeptide)
🧬 Telomerase / Aging

Telomerase activation, chromatin decondensation in aging cells.

ℹ️

These are research-only peptides; comparative notes summarize preclinical literature, not therapeutic recommendations.

❓

FAQ

What is Vesugen (KED)?
Vesugen is a synthetic tripeptide (Lys–Glu–Asp) studied as a vascular and neuroprotective bioregulator that modulates gene expression via DNA/histone interactions.
How does KED influence genes?
Through short-peptide interactions with DNA and histones, including histone/nucleosome binding and promoter docking (e.g., MKI67).
Vascular outcomes?
EDN1 normalization, connexin restoration, increased SIRT1 in preclinical atherosclerosis/restenosis models.
Neuroplasticity outcomes?
Preserved dendritic spines, enhanced arborization in 5xFAD mice; NES, GAP43, p16/p21 modulation.
Clinical evidence?
Limited. Small studies suggested improvements in geriatric contexts, but robust randomized trials are lacking.
Storage requirements?
Lyophilized: ≤ −20°C, desiccated, light-protected. Solutions: cold, short-lived, avoid freeze-thaw.
✅

Bottom line: Vesugen (KED) is a small, epigenetically active research peptide with vascular and neuronal readouts worth testing in well-controlled models—human claims remain preliminary and require rigorous trials.